NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs

CompletedN/A

Sponsor: University Hospital, Montpellier

Conditions: Chronic Inflammatory Rheumatism

Interventions: Biological samples

Countries: France

Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with rheumatoid arthritis or spondyloarthritis
* With positive serology for SARS-CoV-2 infection less than 3 months old at the time of inclusion
* Under biotherapy, or conventional synthetic Disease-modifying antirheumatic drugs (csDMARD) or Nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids for at least one month during the year 2020
* Agreeement to participate two years in the study

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Refusal to participate in the study

Locations (1)

Montpellier, Occitanie, France